For decades, the prescription for excess weight was delivered with a kind of quiet certainty: eat less, move more, try harder. It sounded simple, almost moral in its clarity. But for many, it never worked that way. What medicine now understands, more fully and more compassionately, is that obesity is not merely a failure of discipline. It is a chronic, biologically driven disease, shaped as much by hormones and the brain as by diet and exercise.
Body weight is governed by an intricate internal system. Hormones regulate hunger and fullness, the brain interprets signals about energy needs, and metabolism determines how efficiently the body uses or stores calories. When someone loses weight, this system often pushes back. Hunger intensifies, metabolism slows, and the body behaves as though it is trying to restore a previous, higher weight. This helps explain a frustrating reality familiar to many: weight lost through effort alone is often regained, not for lack of will, but because the body resists change.
In recent years, however, a new class of medications has begun to shift that narrative. Known as incretin-based therapies, these treatments work with the body’s own signaling pathways rather than against them. They mimic naturally occurring hormones, GLP-1 (Glucagon-like peptide-1) and GIP (Glucose-dependent Insulinotropic Polypeptide), that are released after eating and tell the brain when the body has had enough. By enhancing these signals, the medications help reduce appetite, increase feelings of fullness, and improve how the body processes sugar.
Several of these therapies are now available in Singapore, including Liraglutide, Semaglutide, and Tirzepatide. They differ in how often they are taken—some daily, others weekly—and in how strongly they act on the body’s hormonal systems. Clinical studies suggest meaningful results: modest but significant weight loss with liraglutide, more substantial reductions with semaglutide, and even greater outcomes with tirzepatide. For many patients, these results approach what was once achievable only through surgery.
Yet the impact of these medications extends beyond weight alone. Obesity is often accompanied by a cluster of related conditions, type 2 diabetes, hypertension, cardiovascular disease, fatty liver disease, and obstructive sleep apnea among them. Incretin-based therapies have been shown to improve blood sugar control, lower blood pressure, and reduce inflammation. Some studies suggest that semaglutide can lower the risk of heart attacks, while tirzepatide has been approved for treating sleep apnea in certain patients. In this way, the medications are not simply cosmetic tools, but part of a broader strategy to reduce long-term health risks.
Still, these treatments are not a universal solution. Choosing the right therapy requires careful consideration of a patient’s medical history, existing conditions, lifestyle, and financial constraints. These medications can be costly, and access is not always straightforward. For physicians and patients alike, the decision often involves balancing clinical benefit with practical realities.
Side effects, too, must be weighed. The most common are those involving the gut such as nausea, digestive discomfort, changes in bowel habits. They tend to appear early and often subside with time or dose adjustments. More serious risks, though uncommon, include gallbladder disease, pancreatitis, kidney complications related to dehydration and visual disturbances. These medications are not suitable for everyone, particularly those with certain thyroid cancers or women who are pregnant.
What is emerging, then, is not a miracle cure, but a more nuanced understanding of weight itself. The science has moved beyond blame and toward biology, offering tools that align with how the body actually works. For many, this shift represents something meaningful: not just new treatments, but a new way of being understood.
A more guided and individualised approach may offer a different path forward, bringing together medical insight, lifestyle support, and, where appropriate, modern therapies. At Aspen Diabetes & Endocrine Clinic, care is focused on understanding each individual’s journey and supporting them towards more sustainable, long-term health.